Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

被引:210
|
作者
Rassen, Jeremy A. [1 ]
Choudhry, Niteesh K.
Avorn, Jerry
Schneeweiss, Sebastian
机构
[1] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med,Med Sch, Boston, MA 02120 USA
基金
美国国家卫生研究院; 美国医疗保健研究与质量局;
关键词
clopidogrel; drugs; myocardial infarction; platelets; proton pump inhibitors; revascularization; ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; ANTIPLATELET ACTION; CONTROLLED TRIAL; ASPIRIN; THERAPY; RISK; RESISTANCE; EVENTS; DRUGS;
D O I
10.1161/CIRCULATIONAHA.109.873497
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Recent studies have raised concerns about the reduced efficacy of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may have overestimated the risk. Methods and Results-We studied the potential for increased risk of adverse cardiovascular events among users of clopidogrel with versus without concurrent use of PPIs in 3 large cohorts of patients >= 65 years of age, treated between 2001 and 2005. All patients had undergone percutaneous coronary intervention or had been hospitalized for acute coronary syndrome in Pennsylvania, New Jersey, or British Columbia, and subsequently had initiated treatment with clopidogrel. We recorded myocardial infarction hospitalization, death, and revascularization among PPI users and nonusers. We assessed our primary end point of myocardial infarction hospitalization or death using cohort-specific and pooled regression analyses. We entered 18 565 clopidogrel users into our analysis. On a pooled basis, 2.6% of those who also initiated a PPI versus 2.1% of PPI nonusers had a myocardial infarction hospitalization; 1.5% versus 0.9% died; and 3.4% versus 3.1% underwent revascularization. The propensity score-adjusted rate ratio for the primary end point of myocardial infarction or death was 1.22 (95% confidence interval, 0.99 to 1.51); for death, 1.20 (95% confidence interval, 0.84 to 1.70); and for revascularization, 0.97 (95% confidence interval, 0.79 to 1.21). Matched analyses generally yielded similar results. Conclusions-Although point estimates indicated a slightly increased risk of myocardial infarction hospitalization or death in older patients initiating both clopidogrel and a PPI, we did not observe conclusive evidence of a clopidogrel-PPI interaction of major clinical relevance. Our data suggest that if this effect exists, it is unlikely to exceed a 20% risk increase. (Circulation. 2009; 120: 2322-2329.)
引用
收藏
页码:2322 / U34
页数:11
相关论文
共 50 条
  • [21] Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention
    Ekta Gupta
    Darpan Bansal
    John Sotos
    Kevin Olden
    Digestive Diseases and Sciences, 2010, 55 : 1964 - 1968
  • [22] Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention
    Gupta, Ekta
    Bansal, Darpan
    Sotos, John
    Olden, Kevin
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (07) : 1964 - 1968
  • [23] Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention
    Gupta, Ekta
    Olden, Kevin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S405 - S405
  • [24] Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
    Norgard, Nicholas B.
    Abu-Fadel, Mazen
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 873 - 882
  • [26] Influence of different proton pump inhibitors on platelet function in acute myocardial infarction patients receiving clopidogrel treatment after percutaneous coronary intervention.
    Wang, Zhe
    Yang, Xinchun
    Cai, Jun
    Chen, Mulei
    Wan, Xinhong
    BIOMEDICAL RESEARCH-INDIA, 2013, 24 (04): : 453 - 457
  • [27] Risk of Adverse Outcomes in Taiwan Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors in Patients Who Received Percutaneous Coronary Intervention
    Huang, Chin-Chou
    Chen, Yu-Chun
    Leu, Hsin-Bang
    Chen, Tzeng-Ji
    Lin, Shing-Jong
    Chan, Wan-Leong
    Chen, Jaw-Wen
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (12): : 1705 - 1709
  • [28] EFFECT OF TICAGRELOR AND CLOPIDOGREL ON PLATELET AGGREGATION FUNCTION AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Sui, Z.
    Qu, P.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 439 - 445
  • [29] Patients' Perspectives With Acute Coronary Syndrome After Percutaneous Coronary Intervention
    Qin, Hong
    Mayer, Hanna
    Ozturk, Begum
    Eslam, Roza Badr
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2021, 17 (05): : 588 - 593
  • [30] Predictors of mortality in patients with acute coronary syndrome undergoing percutaneous coronary intervention
    Constantinides, SS
    Gieowarsingh, S
    Halim, M
    Been, M
    Shiu, MF
    HEART, 2003, 89 (10) : 1245 - 1246